NEW YORK, NY – June 20, 2026 ( NEWMEDIAWIRE ) – Kaplan Fox & Kilsheimer LLP is investigating possible securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Fulcrum Therapeutics investor and bask in suffered losses, or in case that you just’ll want to bask in records that can perhaps aid within the Fulcrum Therapeutics investigation, that you just’ll want to CLICK HERE to contact us. You would also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
Fulcrum Therapeutics is a “scientific-stage biopharmaceutical firm enraged about constructing small molecules to toughen the lives of sufferers with uncommon hematological disorders[.]”
On June 1, 2026, after market shut, Fulcrum Therapeutics announced in an announcement “the discontinuation of its pociredir program for the therapy of SCD [(sickle cell disease).]” The Company acknowledged that the “meeting minutes from most up-to-date cease-of-phase interactions with the [U.S. Food and Drug Administration (“FDA”)]” “mirrored heightened FDA concerns concerning pociredir’s revenue-possibility profile in SCD, stemming from an by shock excessive payment of secondary hematologic malignancies observed with Tazverik(R) (tazemetostat), one more PRC2 inhibitor, which was once withdrawn from the enviornment market in March 2026.” After submitting additional records, the FDA “concluded that any pharmacological intervention concentrating on the PRC2 complex carries identical malignancy possibility whatever the actual subunit engaged.” In consequence, the Company has “no viable regulatory direction forward for additional scientific pattern of pociredir.”
Following this news, the designate of Fulcrum Therapeutics stock declined from a closing designate on June 1, 2026 of $6.42 per part to shut at $3.14 per part on June 2, 2026, a decline of $3.28 per part, or by 51.09%.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a number one national guidelines firm focusing on complex litigation with workplaces in Fresh York, Oakland, Los Angeles, Chicago and Fresh Jersey. With over 50 years of journey in securities litigation, Kaplan Fox gives the expert journey and video display memoir that purchasers are waiting for of. Via prosecuting instances on the federal and suppose ranges, Kaplan Fox has successfully fashioned the guidelines via a success many necessary decisions on behalf of our purchasers. For more records about Kaplan Fox & Kilsheimer LLP, that you just’ll want to search the advice of with our web stammer at www.kaplanfox.com.
This press free up will be plan to be Licensed expert Selling in some jurisdictions beneath the applicable guidelines and ethical guidelines.
If that you just’ll want to bask in any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
800 Third Avenue, Thirty eighth Flooring
Fresh York, Fresh York 10022
(212) 329-8571
Laurence D. King
1999 Harrison Road, Suite 1501
Oakland, California 94612
(415) 772-4704
Contacting or submitting records to Kaplan Fox & Kilsheimer LLP would not develop an attorney-consumer relationship, nor an responsibility on the phase of Kaplan Fox to aid you as a consumer.
https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/
